Segment Information (Tables)

6 Months Ended

Jun. 30, 2026

The following table is representative of revenue and significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment (in thousands):


	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025			2026			2025
Revenues	$	909		$	422		$	1,472		$	619
Program expenses (1)
Clinical trial studies(1)		502			539			924			1,209
Manufacturing, RenovoCath		260			383			496			720
Other research and development expenses		91			78			148			204
Non-program expenses (2)		1,398			998			2,925			2,104
Personnel compensation and related expenses, including share-based compensation		2,008			1,102			3,797			2,170
Other segment items (3)		(439	)		217			(386	)		(473	)

Net loss	$	(2,911	)	$	(2,895	)	$	(6,432	)	$	(5,315	)

(1)

Includes external research expenses, clinical studies, manufacturing including manufacturing and non-recurring engineering costs, professional and consulting, regulatory, and trade shows for 2026.

(2)

Includes selling, general and administrative expenses for professional and consulting expenses, audit fees, board fees, legal expenses, insurance expenses, travel, marketing expenses for 2026 and other office expenses.

(3)

Includes interest income and interest expense and gain recognized on the fair value of common stock warrant liability.